Puma Biotechnology (PBYI) Competitors $3.11 -0.07 (-2.20%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. PHAR, VALN, ORGO, CRMD, OPT, UPB, BCYC, IMTX, PRTA, and KURAShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Pharming Group (PHAR), Valneva (VALN), Organogenesis (ORGO), CorMedix (CRMD), Opthea (OPT), Upstream Bio (UPB), Bicycle Therapeutics (BCYC), Immatics (IMTX), Prothena (PRTA), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Pharming Group Valneva Organogenesis CorMedix Opthea Upstream Bio Bicycle Therapeutics Immatics Prothena Kura Oncology Puma Biotechnology (NASDAQ:PBYI) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Do analysts recommend PBYI or PHAR? Puma Biotechnology presently has a consensus target price of $7.00, indicating a potential upside of 125.08%. Pharming Group has a consensus target price of $30.00, indicating a potential upside of 241.49%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, PBYI or PHAR? Puma Biotechnology has higher earnings, but lower revenue than Pharming Group. Pharming Group is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$230.47M0.67$21.59M$0.615.10Pharming Group$297.20M2.01-$10.55M-$0.17-51.68 Which has more volatility & risk, PBYI or PHAR? Puma Biotechnology has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Does the MarketBeat Community favor PBYI or PHAR? Puma Biotechnology received 533 more outperform votes than Pharming Group when rated by MarketBeat users. However, 67.65% of users gave Pharming Group an outperform vote while only 67.31% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55667.31% Underperform Votes27032.69% Pharming GroupOutperform Votes2367.65% Underperform Votes1132.35% Do insiders and institutionals hold more shares of PBYI or PHAR? 61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is PBYI or PHAR more profitable? Puma Biotechnology has a net margin of 9.56% compared to Pharming Group's net margin of -6.09%. Puma Biotechnology's return on equity of 41.60% beat Pharming Group's return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Pharming Group -6.09%-7.65%-3.82% Does the media favor PBYI or PHAR? In the previous week, Puma Biotechnology and Puma Biotechnology both had 8 articles in the media. Pharming Group's average media sentiment score of 0.75 beat Puma Biotechnology's score of 0.42 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPuma Biotechnology beats Pharming Group on 10 of the 16 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.24M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio6.487.3222.5518.49Price / Sales0.67239.19394.97102.66Price / Cash4.1965.8538.1834.62Price / Book2.786.436.694.25Net Income$21.59M$143.21M$3.22B$248.31M7 Day Performance3.32%1.24%1.11%1.12%1 Month Performance6.14%6.09%3.59%3.68%1 Year Performance-37.17%-3.34%15.65%5.19% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.8067 of 5 stars$3.11-2.2%$7.00+125.1%-37.3%$154.24M$230.47M6.48200Upcoming EarningsAnalyst RevisionNews CoveragePHARPharming Group2.5191 of 5 stars$8.15+0.7%$30.00+268.1%-6.6%$554.45M$297.20M-31.35280Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpVALNValneva2.5287 of 5 stars$6.63-2.4%$16.00+141.3%-14.9%$538.76M$169.58M-51.00700Upcoming EarningsShort Interest ↓ORGOOrganogenesis3.4237 of 5 stars$4.21-0.2%$5.50+30.6%+108.9%$533.95M$482.04M-70.17950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.5011 of 5 stars$8.14+6.1%$14.50+78.1%+74.9%$530.58M$43.47M-10.0530Upcoming EarningsPositive NewsOPTOpthea0.9143 of 5 stars$3.41+7.2%$1.33-60.9%-0.6%$524.84M$87,666.000.008Gap UpUPBUpstream BioN/A$9.71+10.6%$56.50+481.9%N/A$520.85M$2.37M0.0038News CoveragePositive NewsBCYCBicycle Therapeutics3.0388 of 5 stars$7.51+1.6%$29.14+288.1%-63.5%$519.71M$35.28M-2.28240Earnings ReportShort Interest ↓Positive NewsIMTXImmatics2.0596 of 5 stars$4.24-0.5%$16.67+293.1%-49.6%$515.37M$155.84M-6.42260Positive NewsPRTAProthena3.4204 of 5 stars$9.30+1.1%$55.00+491.4%-54.8%$500.59M$135.16M-4.04130Upcoming EarningsGap DownKURAKura Oncology4.1485 of 5 stars$6.18+4.7%$25.50+312.6%-66.6%$499.21M$53.88M-2.62130Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Pharming Group Competitors Valneva Competitors Organogenesis Competitors CorMedix Competitors Opthea Competitors Upstream Bio Competitors Bicycle Therapeutics Competitors Immatics Competitors Prothena Competitors Kura Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBYI Stock Free PBYI Stock Alerts